



Professional Provider Report

A newsletter for professional providers
and their staff members

January 15, 2019 • S-1-19

What's Inside

- Drug Prior Authorization forms, policies move to Prime website 1
- Web Changes — Medical Policy 2

Drug Prior Auth forms, policies on Prime site, off bcbsks.com Feb. 1

Prior Authorization page on Blue Cross website will have link to new location of forms, policies

Drug Prior Authorization policies and forms currently found on the Blue Cross and Blue Shield of Kansas website now can be found at www.myprime.com, the Prime Therapeutics website.

After Feb. 1, the documents will no longer be located at bcbsks.com. A link to the new location at myprime.com will be provided on the [Prior Authorizations page](#) of the

BCBSKS website.

Some Prior Authorization programs are formulary-specific. If you are unable to locate a program, it may be found under a different formulary listing.

For more information, please contact your Professional Relations representative or Provider Network Services in Topeka at 785-291-4135 or 800-432-3587.

The *Professional Provider Report* is published by the Professional Relations department of Blue Cross and Blue Shield of Kansas.

Dustin Kimmel,
Communications Coordinator



bcbsks.com

Web Changes — Medical Policy

Since the publication of Professional Provider Report [S-5-18](#), the following policies have been posted at: <https://www.bcbsks.com/CustomService/Providers/MedicalPolicies/policies.shtml>

- Ambulatory Event Monitors and Mobile Cardiac Outpatient Telemetry
- Amniotic Membrane and Amniotic Fluid
- Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening
- Androgens and Anabolic Steroids
- Artificial Pancreas Device Systems
- Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
- Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer
- Bio-Engineered Skin and Soft Tissue Substitutes
- BRCA1 and BRCA2 Testing
- Cardiac Hemodynamic Monitoring for the Management of Heart Failure in the Outpatient Setting
- Corneal Collagen Cross-Linking
- Deep Brain Stimulation
- Drug Testing in Pain Management and Substance Use Disorder Treatment
- Emflaza (deflazacort)
- Expanded Molecular Panel Testing of Cancers to Identify Targeted Therapies
- Facet Joint Denervation
- Gene Expression Profiling for Uveal Melanoma
- H.P. Acthar Gel (repository corticotropin)
- Hepatitis C Second Generation Antivirals – Through Preferred Agent(s)
- Human Growth Hormone
- Injectable Atopic Dermatitis Agent(s)
- Intra-Articular Hyaluronan Injections for Osteoarthritis
- Lucemyra (lofexidine)
- Magnetic Resonance Imaging (MRI) of the Breast
- Magnetic Resonance Spectroscopy
- Microwave Tumor Ablation
- Miscellaneous Genetic and Molecular Diagnostic Tests
- Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
- Molecular Markers in Fine Needle Aspirates of the Thyroid
- Natpara (parathyroid hormone)
- Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease
- Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease
- Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
- Opioids, Extended Release (ER)
- Oral Anticoagulant - Bevyxxa® (betrixaban), Eliquis® (apixaban), Pradaxa® (dabigatran), Savaysa™ (edoxaban), Xarelto® (rivaroxaban)
- Oscillatory Devices for the Treatment of Cystic Fibrosis and Other Respiratory Disorders
- Photodynamic Therapy for Choroidal Neovascularization
- Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer
- Sacral Nerve Neuromodulation / Stimulation
- Self Administered Oncology Agents
- Sensorimotor and Neurobehavioral Status Exams for Optometric Providers
- Site of Care Infusion Management
- Sphenopalatine Ganglion Block for Headache
- Spinal Cord and Dorsal Root Ganglion Stimulation
- Strensiq® (asfotase alfa)
- Subtalar Arthroereisis
- Temporomandibular Joint (TMJ) Dysfunction (Availability login required)
- Topical Doxepin
- Total Artificial Hearts and Ventricular Assist Devices
- Urea Cycle Disorders
- Vagus Nerve Stimulation
- Varicose Veins
- Wireless Capsule Endoscopy to Diagnose Disorders of the Small Bowel, Esophagus, and Colon
- Xolair® (omalizumab)

Questions? Contact your professional relations representative or provider network services in Topeka at (785) 291-4135 or (800) 432-3587.

Acknowledgement: Current Procedural Terminology (CPT®) is copyright 2017 American Medical Association (AMA). All rights reserved. No fee schedules, basic units, relative values or related listings are included in the CPT. The AMA assumes no liability for the data contained herein. Applicable ARS/DFARS restrictions apply to government use. Codes published herein are current on the publication/effective date and are subject to change.

Sent to: CAP excluding dentists and pharmacies. Contains public information.